1 Artificial intelligence assisted standard white light 2 endoscopy accurately characters early colorectal cancer: a 3 multicenter diagnostic study

4 Sijun Meng¹, MD, PhD, Yueping Zheng², MD, Ruizhang Su², MD, Wangyue Wang^{3,4}, MD, Yu Zhang³,
5 MD, PhD, Hang Xiao⁵, PhD, Zhaofang Han^{6,7}, PhD, Wen Zhang⁸, PhD, Wenjuan Qin², PhD, Chen
6 Yang⁵, PhD, Lichong Yan⁹, PhD, Haineng Xu¹⁰, PhD, Yemei Bu^{5,11}, MS , Yuhuan Zhong¹², PhD, Yi
7 Zhang¹³, MD, Yulong He¹, MD, PhD, Hesong Qiu⁶, MD, MBA, Wen Xu¹², PhD, Hong Chen¹, MD,
8 Siqi Wu^{6,14}, PhD, Zhenghua Jiang¹⁵, BS , Yongxiu Zhang¹³, MD, Chao Dong¹³, MD, Yongchao Hu¹³,
9 MD, Lizhong Xie¹³, MD, Xugong Li¹⁶, PhD, Jianping Jiang¹³, MD, Huafen Zhu¹³, MPH, Wenxia Li¹,
10 MSMT, Zhang Wen¹, BSMT, Xiaofang Zheng¹³, BN, Yuanlong Sun⁴, MD, Xiaolu Zhou³, MD, Limin
11 Ding⁴, MD, Changhua Zhang¹*, MD, PhD, Wensheng Pan³*, MD, Shuisheng Wu¹²*, MD, Yiqun Hu²
12 *, MD

13

14 1. Center for Digestive Disease, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen,
15 Guangdong, Province, P. R. China, 518107.

16 2. Department of Gastroenterology, Zhongshan Hospital Xiamen University, 201 Hubin South Road,
17 Xiamen, Fujian Province, P. R. China, 361004.

- 18 3. Zhejiang provincial people's hospital, People's Hospital of Hangzhou Medical College, Hangzhou,
- 19 Zhejiang Province, P. R. China, 310014.
- 20 4. Tongxiang First People's Hospital, Tongxiang City, Zhejiang Province, P. R. China, 353000.
- 21 5. Jiying (XiaMen) Technology Co., LTD, Xiamen, Fujian Province, P. R. China, 361004.
- 22 6. Xiamen Cingene Science and technology co., LTD, Xiamen, Fujian Province, P. R. China, 361004.
- 23 7. State Key Laboratory of Marine Environmental Science, College of Ocean and Earth Sciences,
- 24 Xiamen University, Xiamen, P.R. China, 361102.
- 25 8. Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 10029.
- 26 9. Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510, USA
- 27 10. University of Pennsylvania Perelman School of Medicine, Philadelphia, USA.
- 28 11. The School of Pharmacy in Fujian Medical University, Fujian Province, P. R. China.
- 29 12. College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, P.R.
- 30 China, 350122.
- 31 13. Pucheng County Hospital of Traditional Chinese Medicine, Pucheng, Fujian Province, P. R. China,
- 32 353400.
- 33 14. School of Life Sciences, Xiamen University, Xiamen, Fujian Province, P. R. China, 36110.
- 34 15. Department of Clinical Pharmacy, First Hospital of Nanping, Fujian Province, P. R. China, 314500
- 35 16. Department of Financial Engineering, Stevens Institute of Technology, Hoboken, NJ 07030, USA

36 **' Correspondence to:**

37 Changhua Zhang: Center for Digestive Disease, the Seventh Affiliated Hospital of Sun Yat-sen

38 University, No. 628, Zhenyuan Rd, Guangming (New) Dist, Shenzhen, Guangdong Province, P. R.

39 China, 518107. E-mail: zhchangh@mail.sysu.edu.cn. Tel: +86-755-81206101.

40 Shuisheng Wu: College of Pharmacy, Fujian University of Traditional Chinese Medicine, No.1

41 Qiuyang Road, Shangjie University Town, Fuzhou, Fujian, P.R. China, 350122. E-mail:

42 Wushuishengwss@163.com. Tel: +86-591-22861135.

43 Wensheng Pan: Zhejiang provincial people's hospital, People's Hospital of Hangzhou Medical College,

44 No. 158 of Shangtang Road, XiaCheng District, Hangzhou, Zhejiang Province, P. R. China, 310014.

45 E-mail: wspan223@163.com. Tel: +86-571-87666666.

46 Yiqun Hu: Department of Gastroenterology, Zhongshan Hospital Xiamen University, 201 Hubin South

47 Road, Xiamen, Fujian Province, P. R. China, 361004. E-mail: hyq0826@xmu.edu.cn. Tel:

48 +86-592-2590151.

49

50

51

52

53

54

55 **ABSTRACT**

56 Colorectal cancer (CRC) is the third in incidence and mortality¹ of cancer. Screening with colonoscopy
 57 has been shown to reduce mortality by 40-60%². Challenge for screening indistinguishable
 58 precancerous and noninvasive lesion using conventional colonoscopy was still existing³. We propose to
 59 establish a propagable artificial intelligence assisted high malignant potential early CRC
 60 characterization system (ECRC-CAD). 4,390 endoscopic images of early CRC were used to establish
 61 the model. The diagnostic accuracy of high malignant potential early CRC was 0.963 (95% CI,
 62 0.941-0.978) in the internal validation set and 0.835 (95% CI, 0.805-0.862) in external datasets. It
 63 achieved better performance than the expert endoscopists. Spreading of ECRC-CAD to regions with
 64 different medical levels can assist in CRC screening and prevention.

65 **Introduction**

66 Colorectal cancer (CRC) is one of the most common malignant tumors in the globe⁴. “Cancer Statistics,
 67 2020” indicates that CRC ranks the third in incidence and mortality¹. Accurate identification and
 68 treatment of early CRC have significantly reduced incidence and mortality⁵. However, early CRC is
 69 generally asymptomatic, and coloscopy allows direct visual inspection of the intestinal tract and
 70 same-session detection, biopsy, and subsequent removal of disease lesion. Several countries
 71 recommend that adults over the age of 50 should regularly screen CRC by coloscopy^{6,7}. While

72 colonoscopy is a kind of expert dependent examination, which can lead to missed diagnosis and
73 misdiagnosis due to various causes, such as the experience of endoscopist, the interference during
74 operation and inevitable interval of eye movement⁸. Computer assisted diagnose (CAD) system can
75 solve above-mentioned problems.

76 In recent years, some Artificial Intelligence (AI)-based CAD systems have come into the pre-clinical
77 application stage. However, the limitations of the research design (i.e. lack of external validation, not
78 solving the critical clinical problems) lead to the consequence that the existing assistances are not really
79 suitable for clinical practice directly^{9,10}. In the field of gastrointestinal tumor, most studies focus on the
80 detection of polyps and adenomas^{11,12}, the staging of advanced cancer¹³ and the optimizing of
81 endoscopic operation^{14,15}. Effects of these CAD systems in decreasing mortality rate of CRC need to be
82 proven¹⁶ by more clinical trials. Early gastrointestinal cancer diagnosis system that can directly
83 decrease the occurrence of CRC is limited¹⁷, because the quantity of images from a single medical
84 center is insufficient to support the establishment of the algorithm. Therefore, we aim to establish an
85 early CRC CAD and malignant potential characteristic system (herein referred to as ECRC-CAD)
86 based on standard white-light endoscopy (WLE), which can be clinically applied to different regions.

87 In this multi-center diagnostic clinical research, we establish an AI assisted early CRC diagnosis model
88 using deep learning, which is based on images of different quality endoscopy from hospitals in
89 different medical levels (i.e., rural, municipal, provincial) in China. Furthermore, ECRC-CAD can

90 identify intraepithelial neoplasm (IN), which is one of the most typical malignant precancerous
 91 conditions that can be differentiated by using image-enhanced endoscopy (IEE) and diagnosed by
 92 histology test. The clinical applicability of this model has been verified in the internal and external
 93 datasets collected retrospectively and another internal dataset collected prospectively.

94 **Methods**

95 **Study design and participants**

96 This study was a multi-center clinical diagnosis research, which was completed in five hospitals at
 97 different medical levels across three provinces of China.
 98 The workflow is shown in Figure 1. The first part is a case-control, retrospective research. All patients
 99 who underwent colonoscopy examination excepting for repeated examination in four hospitals from
 100 January 2016 to July 2019 are enrolled, including Zhongshan Hospital of Xiamen University (XMZSH)
 101 in Fujian, Zhejiang Provincial People's Hospital (ZJPH) in Zhejiang, the Seventh Affiliated Hospital of
 102 Sun Yat-sen University (SYSUSH) in Guangdong, and Pucheng County Traditional Chinese Medicine
 103 Hospital (PCTCRMH) in Fujian. Among them, SYSUSH started operation in July 2018. Patients who
 104 were diagnosed with early CRC by histopathological examination were selected. Pathological
 105 diagnosis was referred to the 4th WHO Classification of Tumors of Digestive System¹⁸. Early CRC in
 106 this article referred to precancerous conditions, in accordance with the requirements of the international
 107 standard. Patients with progressive colorectal cancer were excluded. Images of early CRC confirmed to

108 the database's including criteria (see in below) were included into case-control study, and were
109 randomly assigned to the training set, evaluation & tuning set, and internal testing set in the ratio of
110 8:1:1. All images of intraepithelial neoplasm (referred as IN-ECRC) were included to case group, and
111 other early CRC without intraepithelial neoplasm (referred as NIN-ECRC) were randomly sample in
112 corresponding quantity included to control group. ECRC-CAD was constructed and optimized using
113 the first two data sets. To verify the veracity and clinical applicability of the model, we used validation
114 datasets including images from the above internal testing set and another external testing set, which are
115 consisted of images are according to the above criteria from Tongxiang Hospital (TXH) in Zhejiang.
116 The second part is a prospective research. The identification model officially completed the detection
117 and model optimization of the above samples in September 2019, and was connected to the above five
118 hospitals through the Internet. Then we prospectively collected the AI recognition results of all
119 endoscopic center images in October 2019 and the first half of November 2019 from the above five
120 hospitals, and extracted some endoscopic images of IN-ECRC and NIN-ECRC for senior doctors to
121 identify.
122 Each participating institute has got ethical approval by independent ethics Committee according to the
123 Helsinki declaration. The informed consent of retrospective cohort was exempted by the institutional
124 review boards, causes it's the secondary use of clinical data without any intervention. In the
125 prospective study, each patient was informed and signed up informed consent.

126 **Endoscopy and early CRC's image database**

127 Endoscopic images of five hospitals were captured by EC590WM, EC-600WM, EC-L590Z (WFujinon
128 Corp, Saitama, Japan); V-70, PCF-H260AZI, CF-H260AI, CF-H290I, CF-HQ290I (Olympus Medical
129 Systems, Tokyo, Japan); EC34-i10M , EG2990Z I (PENTAX medical, Tokyo, Japan). Each image of
130 patients with early CRC was sequenced according to anatomical location, and screened by three
131 endoscopy physicians. Exclusion criteria include: 1. The endoscopic anatomical location was not
132 consistent with the pathological report, 2. Pictures were taken under IEE, 3. Pictures without any early
133 CRC lesion, 4. Pictures was not confirmed to the sampling standard¹⁹ summarized by our research team.
134 All images in the database present at least one lesion, and multiple images might be taken for the same
135 lesion, including differences of angle, distance, and extension of the intestinal wall. Images were saved
136 in a jpeg format.

137 **Image Labeling**

138 Two senior endoscopists with more than 10 years of clinical experience, four residents and two
139 assistants carried out image selection and labeling with blind method. The doctors were divided into
140 three groups randomly, and at least one senior doctor in each group. The deep learning marking tool
141 LabelMe²⁰ of Anaconda was used to mark the outline of disease lesion manually. Two physicians in the
142 same group worked together. One was mainly responsible for drawing, and the other was mainly
143 responsible for checking. Only when two physicians from the same group reached a consensus, the

144 labeling of the image could be finalized. After the first identification by ECRC-CAD, the misdiagnosed

145 images were double-checked so as to ensure the correctness and rationality of the results.

146 **Construction and optimize of algorithm**

147 The ECRC-CAD's algorithm was based on the concept of full convolution networks²¹ (FCN), which is

148 composed of classification module and post-processing module (Supplements p1-p2). The pattern

149 diagram was shown in Figure 2. Comparing with the classical CNN, this method can be adapted to

150 inputs with any size. In order to get an accurate boundary, we precisely outlined disease lesion of

151 images in establishing sets. The model contains one input and one output. The input of the model was

152 the image that contains the lesion. The output implemented a segmentation task that each pixel is

153 classified as background, intraepithelial neoplasm or other early CRC. Intraepithelial neoplasm was

154 abbreviated as "IN-ECRC", and the other early colorectal cancer neoplasm was abbreviated as

155 "NIN-ECRC". The labeling from histopathological examination was adopted as the gold standard in

156 training ECRC-CAD.

157 The implementation of AI-assisted precursor lesion identify model was fulfilled by using Python 3.7

158 (Python Software Foundation; www.python.org/).

159 **Algorithm testing and outcome measurement**

160 Three validation datasets were used to verify ECRC-CAD, which include internal datasets, external

161 datasets, and prospectively collected datasets. In the internal and external validate datasets, the

162 performance of ECRC-CAD was compared with the pathological golden standard of the corresponding
 163 tissues, and calculated statistic indicators on the individual images. When FCN detects early CRC from
 164 the input data of the validation image, the model outputs the lesion name. When the output result of the
 165 model is consistent with the pathological result, it is considered to be correct. In the prospective dataset,
 166 the performance was compared with histopathological result and expert at the same time. We randomly
 167 selected a subset of patients' images with histologically confirmed early CRC from the prospective
 168 collected datasets. Two experienced endoscopists were asked to complete independently the same test
 169 images together. These images' histology diagnosis is blinded to the two endoscopists. The diagnosis
 170 results of ECRC-CAD and experts were taken the patient as the unit, which is according with clinical
 171 requirements.

172 Sometimes, it's difficult to identify the whole images of disease lesion caused by the image quality and
 173 angle. When the model can identify even one picture of the cancer, it is considered as correct.

174 **Statistical analysis**

175 In this study, descriptive analysis was used to describe the baseline characteristics of the enrolled
 176 subjects. Continuous variables were expressed by median (interquartile interval), dichotomous
 177 variables and grade variables that expressed by percentage. In order to evaluate the authenticity of
 178 ECRC-CAD, the diagnostic evaluation method was adopted. The evaluating indexes included
 179 Sensitivity, Specificity, Condolence, Positive predictive value (PPV), and Negative predictive value

(NPV). According to the above indexes, receiver operating characteristic (ROC) of different subgroups were drawn, and the area under the ROC curve (AUC) was calculated to evaluate the classification effect of this model on different subjects. More details are in the supplements p3. All statistical analyses in this study were based on the two-sided test 0.05 and performed through R software version 3.6.0 (R Development Core Team).

Results

Patient and image dataset information

More than 6.2 million patients have done lower gastrointestinal tract in XMZSH, ZJRMH, SYSUSH, and PCRMH from January 2016 to August 2019. Almost 40% percent without any disease lesion were excluded. All participants diagnosed with IN-ECRC were enrolled in the model establishing sets, after quality control, 1923 images were enrolled, participants with NIN-ECRC corresponding in number of IN-ECRC were randomly extracted from other patients. The ratio of male to female is about 2.08:1. Age ranges from 20 to 86, and represent the right-skewed distribution (median age is 53.5). The baseline information of the establishing cohort and external cohort were listed in Table 1. Finally, in the stage of model establishment, 1923 images included in the case group, and 2467 images were included in the control group. In the model optimization stage, 490 images were included. In the verification stage, 189 images and 247 images were respectively collected in the above four hospitals as internal datasets. External datasets, including 960 images from 134 patients, were used to contract

198 and test ECRC-CAD. The prospectively collected datasets enrolled 672 patients, including 319

199 IN-ECRC and 353 NIN-ECRC patients.

200 **Performance of the precancerous detection model**

201 ECRC-CAD output results within 0.16 seconds and marks the boundary of disease lesion. The

202 diagnosis result of each image was listed in supplementary material (eTable 1). The diagnostic

203 accuracies of the internal validation dataset were 0.963 (95% CI, 0.941 to 0.978). External testing set

204 only includes only IN-ECRC, which causes pathologists found that diagnostic criteria of NIN-ECRC in

205 TXH are not based on the 4th WHO Classification of Tumors of Digestive System. The sensitivity of

206 ECRC-CAD in THX is 0.835 (95% IC, 0.805 to 0.862). The four indicates of the internal validation

207 dataset is higher than 0.93. Similarly, a high AUC value (0.939) was also observed in the internal

208 datasets (Figure 4). In the prospective study, the index of diagnosis accuracies was calculated in human

209 units, which is more suitable for clinical needs. High accuracy (0.885, 95% CI, 0.859 to 0.907) was

210 observed. The sensitivity and PPV were more than 0.90, and specificity and NPV were more than 0.85.

211 The causes of misidentification are similarities, including incomplete exposure of disease lesions,

212 concomitant other diseases, and some normal structures. The PPV (0.609, 95% IC, 0.454 to 0.745) and

213 NPV (0.426, 95% IC, 0.303 to 0.559) were significantly lower for the expert endoscopists when

214 compared with the AI-assisted model ($P<0.0001$). Sensitivity and specificity between the endoscopic

215 experts and the ECRC-CAD were visible.

216 This model has been successfully embedded in the above five hospitals, which is connected to the
 217 endoscopically connected computers through the Internet. Doctors and clinicians can identify the
 218 routine screenshots during the operation. The results of model recognition are displayed in the upper
 219 right corner of the screen in real time. In order to benefit more people, ECE-CAD is now available at:
 220 <http://123.57.221.125/#/home>. Home page is on display in Supplementary material (eFigure 2).
 221 Endoscopists can upload endoscopic images of suspected early CRC, and the system will give
 222 judgment in real time. Furthermore, we provided a set of WLE images of early CRC through open
 223 ports, which can help inexperienced endoscopist to familiar with it. The openness of this recognition
 224 model can also help endoscopists in less developed areas or those with low seniority to learn the
 225 recognition of early CRC (eFigure 3).
 226 Both Asian and Western researchers consider that specific gross morphology, mucosal surface
 227 structure and microvascular structure or multi-changes of neoplasm have corresponding molecular
 228 characteristics²². We analyzed the microstructure feature of WLE, IEE in the same lesion taken from
 229 the same angle, and the association with features of H&E stained pathological image (eFigure 4).
 230 Combined with the published results (eTable 2), we proposed that the application of endoscopic images
 231 to predict molecular characteristics through endoscopic or pathology images in real-time is the future
 232 direction of “Image genomics”²³.

233 Discussion

Overall, 1680 images of IN-ECRC and 2220 images of NIN-ECRC were used to establish and optimize ECRC-CAD. In order to ensure the clinical application of the model in underdeveloped regions, these images were collected from different medical level hospitals in China. Review published articles, it's the largest, multi-source endoscopic image database used to establish AI aided diagnose system in globe²⁴. Furthermore, three clinical validation studies were conducted on the immediate clinical application value of ECRC-CAD, which showed high accuracy in the internal dataset (0.963). Liu et al²⁵ systematically reviewed the in-depth learning performance of diagnosis of disease from medical imaging. Of the 82 eligible researches from 2012 to 2019, only 25 have external validation. We avoided the issues mentioned above in this meta-analysis. The displayed ECRC-CAD can be extended to the external dataset from another rural hospital with a sensitivity of 0.835. This verification cohort could avoid highly accurate prediction which are caused by excessively spurious associations with the known outcome. However, case-control would not be representative of the general screening population²⁶, and the predictor may not be directly applied to clinical practice. In this study, we validated ECRC-CAD in a prospective cohort, and ECRC-CAD and experts identified the disease's nature in real-time, respectively. The result showed that ECRC-CAD maintained perfect accuracy and specificity in prospective study, even better than expert endoscopist.

In clinical daily work, ECRC-CAD can assist endoscopist through increasing early CRC's detection rate, decreasing missed diagnosis rate (Figure S5). Endoscopy and clinical practice of operator have a

252 great influence on the detection and treatment of early cancer. A prospective study of UK²⁷ shows that

253 the good performance of operating require skilled intubation operation and independent practice. While

254 endoscopist in developed region can get more information about microstructure under IEE, which can

255 increase diagnosis rate of early CRC by 10%-20%²⁸ comparing with WLE. However, early screening

256 of neoplasm is mostly carried out in community hospitals with relatively low medical level, and the

257 endoscopic equipment is relatively backward. Early CRC detection rate of ECRC-CAD has the same

258 performance with IEE. Using ECRC-CAD enable people in lower medical level regions to get similar

259 screening efficiency compared with subjects in developed regions.

260 Apart from assisting clinical decision, AI can make clinical path optimization possible^{23,29}. The

261 introduction of colorectal endoscopic submucosal dissection (ESD) increased the complete resection

262 rate of early CRC³⁰ with minimally invasive trauma and low local recurrence possibility. High-grade

263 IN without invasion or only superficial submucosal infiltration diagnosed by pathology examination is

264 an indicator for ESD. The interval time between first endoscopic biopsy and pathology diagnosis is

265 usually one week. At present, multi classification based on IEE³¹⁻³³ has been widely used to predict the

266 risk of malignancy and invasiveness of CRC. Neoplasm confirm to indicators of malignant

267 aggressiveness subtype according to these classifications can be removed during first endoscopic

268 operation. It saved medical resources, and more important, absence of IEE or experts may increase

269 metastasis of implanted cancer cell in natural cavity³⁴ due to incomplete resection. But there're some

270 limitations: Kudo, Sano classification is based on single observation index of pit or vessel pattern,
 271 NICE classification combining with gland and capillary pattern cannot differentiate IN from NIN, and
 272 all classifications need expert practice and IEE. ECRC-CAD can identify IN under WLE within 0.16
 273 second, which make up for the above deficiencies of present classification.

274 WL Bi²³ mentioned that characterization and monitoring are the future direction of AI in medical
 275 image. ECRC-CAD have realized characterization of precancerous lesion, and it can steadily monitor
 276 the progression of CRC without interference. However, with accumulation of medicine data
 277 preternaturally over time, AI will add rich layers of intelligence through combining molecular and
 278 pathological information with image-based findings. "Image genomics"²³ is the key to realize it,
 279 referring to the association of imaging characteristics with biological data, including specific molecular
 280 markers that are mainly based on immunohistochemical, or sequencing technology that are developed
 281 to direct personalized treatment planning. In lung cancers, researchers have established algorithm to
 282 predicted EGFR genotype using computed tomography image (MRI). Can endoscopic images be used
 283 in image genomics? We reviewed all researches of surface microstructure under endoscopy and
 284 molecular characteristics associated with colorectal neoplasms. These results indicate that that the AI
 285 have the potential of identify phenotypic and molecular specific pathological changes under WLE,
 286 causes of AI can extract a large number of features that cannot be observed by the human naked eyes.

287 The development of predicting multigroup tumor molecular markers through endoscopic images will
 288 paved the way for the future “one-step” clinical workflow with AI interventions.

289 The insufficiencies in this study includes: 1. ECRC-CAD can’t increase adenoma detection rate (ADR),
 290 because it’s based on static image taken by endoscopist. We’ve explored a CAD based on video, and
 291 the clinical validation is processing. 2. The external validation set is not included with NIN-ECRC. We
 292 are reassessing this part of cases by two expert histopathologists, to add a complete evaluation to this
 293 model. 3. Sample of high-grade IN is limited for making differentiation of ECRC-CAD in low or
 294 high-grade of IN. 4. We just focus on identifying IN-ECRC from NIN-ECRC, which can’t distinguish
 295 between sessile serrated lesions and other lesions. However, about 80% of sporadic CRC develop from
 296 IN¹⁸, removal of which may decrease the incidence of colorectal cancer by 53%. 5. The prospective
 297 validation is not a randomized controlled trial (RCT). We’re planning to proceed with subsequent RCT
 298 studies in more centers. 6. We just put forward the endoscopic image that can be used to predict
 299 molecular subtype, but ECRC-CAD cannot identify surface microstructure yet. Considering the clinical
 300 applicability, the model was constructed using images taken by WLE in this study, which were not
 301 suitable for micro-structure classification. In subsequent RCT studies, high-resolution WLE and IEE
 302 images of early neoplasm will be prospectively collected to construct the classification model for
 303 microstructure.

304 This is an exploratory study on identification and diagnosis of early cancers that could be applied to
305 other organs of digestion system, such as the stomach and esophagus.

306

307 **Acknowledgement**

308 This research was supported by Major Science and Technology Project of Zhejiang Provincial
309 (2020C03030), Natural Science Foundation of Fujian Province (2019-CXB-31), Science and
310 technology program of Guangdong Province (2016A020213002), and National Natural Science
311 Foundation of China (81773956). We would like to thank: (1) Yonghe Zhou, Kunping Hang for
312 coordinating the data in the primary hospitals; (2) Tonghai Dou, Ph.D, Chuncheng Cheng, ZI CHONG
313 KUO providing valuable advice; and Volunteer Joey Yau helps in data collation; (3) The Pucheng
314 county health administration has provided assistance to primary hospitals; (4)The families of all the
315 participants provided spiritual encouragement and material support, allowing researchers to continue
316 their experiments in the most difficult times.

317

318 **Contributors**

319 Yiqun Hu is general manager the of the project. Hesong Qiu is the project coordinator and participates
320 in the optimization of research design. Sijun Meng, Wangyue Wang, Yu Zhang, Zhaofang Han,
321 Wenjuan Qin, Yuhuan Zhong, Yi Zhang, Zhenghua Jiang, Yongxiu Zhang, Chao Dong, Yongchao Hu,

322 Lizhong Xie, Jianping Jiang, Huafen Zhu, Wenxia Li, Zhang Wen, Xiaofang Zheng, Yuanlong Sun,
323 Xiaolu Zhou, Limin Ding have contributed in participants' enrollment, imaging collecting and quality
324 control. Yueping Zheng, Ruizhang Su, Siqi Wu, Yemei Bu, Xiaofang Zheng have classified and
325 integrated data. Hang Xiao and Chen Yang are responsible for algorithm establishing and optimizing.
326 Sijun Meng, Wen Zhang, Lichong Yan, Haineng Xu, and Xugong Li contribute to manuscript writing.
327 Ruizhang Su, Yemei Bu, Wenjuan Qin, Hong Chen, Wensheng Pan, Yiqun Hu were organized and
328 labeled photos. Yiqun Hu, Wensheng Pan, Hong Chen identified the IN-ECRC as expert endoscopist.
329 Shuisheng Wu, Wensheng Pan and Changhua Zhang's contributed equally in the project.
330 The corresponding author is Changhua Zhang, Shuisheng Wu, Wensheng Pan, Yiqun Hu. According to
331 the author ranking, Hesong Qiu and the previous author are first co-authors, Xugong Li and the
332 previous author are second co-authors, the others is the third co-authors.

333

334 **Ethical approval**

335 This study was approved by the medical ethic committee of each participants (IRB serial number:
336 XMZSYYKY_ER No.2019023).

337

338 **Declaration of interests**

339 We declare no competing interests.

340

341 **Reference:**

342 1. Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2020. *CA: A Cancer*

343 *Journal for Clinicians* **70**, 7-30 (2020).

344 2. Brenner, H., Stock, C. & Hoffmeister, M. Effect of screening sigmoidoscopy

345 and screening colonoscopy on colorectal cancer incidence and mortality:

346 systematic review and meta-analysis of randomised controlled trials and

347 observational studies. *BMJ (Clinical research ed.)* **348**, g2467-g2467 (2014).

348 3. Su, M.-Y., *et al.* Comparative study of conventional colonoscopy,

349 chromoendoscopy, and narrow-band imaging systems in differential diagnosis

350 of neoplastic and nonneoplastic colonic polyps. *The American journal of*

351 *gastroenterology* **101**, 2711-2716 (2006).

352 4. Bray, F., *et al.* Global cancer statistics 2018: GLOBOCAN estimates of

353 incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a*

354 *cancer journal for clinicians* **68**, 394-424 (2018).

355 5. Lin, J.S., *et al.* Screening for Colorectal Cancer: Updated Evidence Report and

356 Systematic Review for the US Preventive Services Task Force. *JAMA* **315**,

357 2576-2594 (2016).

- 358 6. Wolf AMD, F.E., Church TR, et al. . Colorectal cancer screening for
359 average-risk adults: 2018 guideline update from the American Cancer Society.
360 *CA Cancer J Clin* **68(4)**, 250–281 (2018).
- 361 7. Wender RC, B.O., Fedewa SA, Gansler T, Smith RA. . A blueprint for cancer
362 screening and early detection: Advancing screening's contribution to cancer
363 control. *CA Cancer J Clin* **69(1)**, 50–79 (2019).
- 364 8. Lee, J., *et al.* Risk factors of missed colorectal lesions after colonoscopy.
365 *Medicine (Baltimore)* **96**, e7468-e7468 (2017).
- 366 9. Rajkomar A, D.J., Kohane I. Machine Learning in Medicine. *N Engl J Med*
367 **380(14)**, 1347–1358 (2019).
- 368 10. AI diagnostics need attention. *Nature* **555(7696)**, 285 (2018).
- 369 11. Byrne, M.F., *et al.* Real-time differentiation of adenomatous and hyperplastic
370 diminutive colorectal polyps during analysis of unaltered videos of standard
371 colonoscopy using a deep learning model. *Gut* **68**, 94-100 (2019).
- 372 12. Wang, P., *et al.* Real-time automatic detection system increases colonoscopic
373 polyp and adenoma detection rates: a prospective randomised controlled study.
374 *Gut* **68**, 1813-1819 (2019).

- 375 13. Zhu Y, W.Q., Xu MD, et al. Application of convolutional neural network in
376 the diagnosis of the invasion depth of gastric cancer based on conventional
377 endoscopy. *Gastrointest Endosc* **89**(4), 806–815.e801. (2019).
- 378 14. Wu, L., *et al.* Randomised controlled trial of WISENSE, a real-time quality
379 improving system for monitoring blind spots during
380 esophagogastroduodenoscopy. *Gut* **68**, 2161-2169 (2019).
- 381 15. Wu, L., *et al.* A deep neural network improves endoscopic detection of early
382 gastric cancer without blind spots. *Endoscopy* **51**, 522-531 (2019).
- 383 16. Rees, C.J. & Koo, S. Artificial intelligence - upping the game in
384 gastrointestinal endoscopy? *Nature reviews. Gastroenterology & hepatology*
385 **16**, 584-585 (2019).
- 386 17. de Lange, T., Halvorsen, P. & Riegler, M. Methodology to develop machine
387 learning algorithms to improve performance in gastrointestinal endoscopy.
388 *World J Gastroenterol* **24**, 5057-5062 (2018).
- 389 18. Bosman, F.T., Carneiro, F., Hruban, R.H. & Theise, N.D. *WHO classification*
390 *of tumours of the digestive system*, (World Health Organization, 2010).
- 391 19. Zheng, Y., *et al.* Setting Standards to Promote Artificial Intelligence in Colon
392 Mass Endoscopic Sampling. *medRxiv*, 19008078 (2019).

- 393 20. Russell, B.C., Torralba, A., Murphy, K.P. & Freeman, W.T. LabelMe: A
394 Database and Web-Based Tool for Image Annotation. *International Journal of*
395 *Computer Vision* **77**, 157-173.
- 396 21. Shelhamer, E., Long, J. & Darrell, T. Fully Convolutional Networks for
397 Semantic Segmentation. *IEEE Transactions on Pattern Analysis and Machine*
398 *Intelligence* **39**, 640-651 (2017).
- 399 22. Suzuki, H., Yamamoto, E., Yamano, H.-O., Nakase, H. & Sugai, T. Integrated
400 Analysis of the Endoscopic, Pathological and Molecular Characteristics of
401 Colorectal Tumorigenesis. *Digestion* **99**, 33-38 (2019).
- 402 23. Bi, W.L., *et al.* Artificial intelligence in cancer imaging: Clinical challenges
403 and applications. *CA: a cancer journal for clinicians* **69**, 127-157 (2019).
- 404 24. Ahmad, O.F., *et al.* Artificial intelligence and computer-aided diagnosis in
405 colonoscopy: current evidence and future directions. *Lancet Gastroenterol*
406 *Hepatol* **4**, 71-80 (2019).
- 407 25. Liu, X., *et al.* A comparison of deep learning performance against health-care
408 professionals in detecting diseases from medical imaging: a systematic review
409 and meta-analysis. *The Lancet Digital Health* **1**, e271-e297 (2019).

- 410 26. Zhou, Q., Cao, Y.-H. & Chen, Z.-H. Optimizing the study design of clinical
411 trials to identify the efficacy of artificial intelligence tools in clinical practices.
412 *EClinicalMedicine* **16**, 10-11 (2019).
- 413 27. Siau, K., Hawkes, N.D., Dunckley, P. & Valori, R.M. Impact of fellowship
414 training level on colonoscopy quality and efficiency metrics: a United
415 Kingdom perspective. *Gastrointestinal endoscopy* **89**, 441-442 (2019).
- 416 28. Guo, T.-J., *et al.* Diagnostic performance of magnifying endoscopy with
417 narrow-band imaging in differentiating neoplastic colorectal polyps from
418 non-neoplastic colorectal polyps: a meta-analysis. *Journal of gastroenterology*
419 **53**, 701-711 (2018).
- 420 29. Rajkomar, A., Dean, J. & Kohane, I. Machine Learning in Medicine. *The New*
421 *England journal of medicine* **380**, 1347-1358 (2019).
- 422 30. Sakamoto, T., *et al.* Endoscopic submucosal dissection for colorectal
423 neoplasms: a review. *World journal of gastroenterology* **20**, 16153-16158
424 (2014).
- 425 31. Kudo, S., *et al.* Diagnosis of colorectal tumorous lesions by magnifying
426 endoscopy. *Gastrointest Endosc* **44**, 8-14 (1996).

- 427 32. Sano, Y., *et al.* Magnifying observation of microvascular architecture of
428 colorectal lesions using a narrow-band imaging system. *Digestive endoscopy*
429 **18**, S44-S51 (2006).
- 430 33. Hayashi, N., *et al.* Endoscopic prediction of deep submucosal invasive
431 carcinoma: validation of the narrow-band imaging international colorectal
432 endoscopic (NICE) classification. *Gastrointestinal endoscopy* **78**, 625-632
433 (2013).
- 434 34. Lee, H.J., *et al.* Is endoscopic submucosal dissection safe for papillary
435 adenocarcinoma of the stomach? *World journal of gastroenterology* **21**,
436 3944-3952 (2015).

437

438

439

440

441

442

443

444

445

446

447

448 **FIGURE LEGENDS**

449 **Figure 1. Workflow of establishment and valuation of ECRC-CAD**

450 The flow chart shows the construction and validation process and committed steps of ECRC-CAD.

451 **Figure 2. Diagram of ECRC-CAD**

452 Algorithm of ECRC-CAD is based on FCN8. Score of IN-ECRC+ score of NIN-ECRC=1, If score of

453 IN-ECRC >score of NIN-ECRC, we recognize it as IN-ECRC, if score of NIN-ECRC>score of

454 IN-ECRC, we recognize it as NIN-ECRC.

455 **Figure 3. Demonstration of ECRC-CAD's extraction and characterization results**

456 The left image of each pair is the original image under the endoscope, the right image of each pair is

457 the disease lesion extracted by ECRC-CAD. Predict result was listed under each pair of images. The

458 "Prediction" result represents the type of extracted lesion identified by ECRC-CAD, the "confidence"

459 represents the score that were calculated by ECRC-CAD.

460 **Figure 4. Receiver operating characteristic curves of ECRC-CAD**

461 ECRC-CAD performance on the internal validate sets (436 images). AUC indicates area under the

462 receiver operating characteristic curve.

463

464

FIGURES

Figure 1. Workflow of establishment and valuation of ECRC-CAD

Figure 2. Diagram of ECRC-CAD

474 **Figure 3. Demonstration of ECRC-CAD's extraction and characterization**

475 **results**

476

477 **Figure 4. Receiver operating characteristic curves of ECRC-CAD**

478

479 **Table 1. Baseline information**

		Establish cohort			Validate cohort		Expert
		Establishing set (unit: image)	Evaluate & Tuning set (unit: image)	Internal testing set (unit: image)	External testing set (unit: image)	Prospective testing set (unit: person)	endoscopists (unit: person)
Sum of subjects		3464	490	436	674	454	107
Stage	IN-ECRC	1491	243	189	674	98	63
	NIN-ECRC	1973	247	247	NaN	353	44

489

Table 2. Performance of ECRC-CAD in different validation dataset and expert endoscopist in distinguishing IN-ECRC and NIN-ECRC

	Internal testing set	External testing set	Prospective testing set	Expert endoscopist	ECRC-CAD vs Endoscopist*
Accuracy (95% CI)	0.963 (0.941-0.978)	0.835(0.805-0.862)	0.885 (0.859-0.907)	0.505 (0.411-0.598)	$P<0.0001$
Sensitivity (95% CI)	0.937 (0.889-0.965)	0.835(0.805-0.862)	0.915 (0.878-0.942)	0.444 (0.321-0.575)	$P<0.0001$
Specificity (95% CI)	0.984 (0.956-0.995)	NaN	0.858 (0.817-0.892)	0.591 (0.433-0.733)	$P<0.0001$
PPV (95% CI)	0.978 (0.941-0.993)	NaN	0.854 (0.811-0.887)	0.609 (0.454-0.745)	$P<0.0001$
NPV (95% CI)	0.953 (0.917-0.974)	NaN	0.918 (0.882-0.944)	0.426 (0.303-0.559)	$P<0.0001$

490

*McNemar's test